Board Meeting14 Nov 2026, 07:03 pm
Aarey Drugs Board Approves Q2 FY27 Unaudited Financial Results
AI Summary
Aarey Drugs & Pharmaceuticals Ltd announced that its Board of Directors met on November 14, 2026, to approve the Unaudited Financial Results for the second quarter and half-year ended September 30, 2026, on a standalone basis. The board also approved the Limited Review Report and MD/CFO certification. Additionally, a Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue) was approved. The trading window will reopen 48 hours after the announcement of these results.
Key Highlights
- Board meeting held on November 14, 2026.
- Approved unaudited standalone financial results for Q2 & H1 FY27.
- Reviewed and approved Limited Review Report and certifications.
- Approved statement on utilization of funds from warrants.
- Trading window to reopen post-announcement.
Price Impact
More from AAREYDRUGS